Back to search
FDAFDA · Food and drugs·Recall number D-0529-2020

Ranitidine Syrup (Ranitidine Oral Solution, USP), 15 mg/mL (75 mg/5mL) 474 mL bottle, Rx only Distributed by: Aurobindo Pharma USA Inc. 279 Princeton-Hightstown Road East Windsor, NJ 08520 Made in India NDC 65862-431-74

Published December 4, 2019 · Recall initiated: November 6, 2019

Summary

FDA records drug Class II recall D-0529-2020, published December 4, 2019 and initiated November 6, 2019. Recalling firm: AuroMedics Pharma LLC; Status: Ongoing; Reported quantity: 19320 bottles; Lot: UI1519001-A UI1519002-A UI1519003-A UI1519004-A. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: N-nitrosodimethylamine (NDMA) has been detected in Ranitidine tablets, capsules and syrups.

What to do

Voluntary: Firm initiated · Press Release

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
AuroMedics Pharma LLC
Distributor
nationwide
Lot
UI1519001-A UI1519002-A UI1519003-A UI1519004-A
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Ranitidine Syrup (Ranitidine Oral Solution, USP), 15 mg/mL (75 mg/5mL) 474 mL bottle, Rx only Distributed by: Aurobindo Pharma USA Inc. 279 Princeton-Hightstown Road East Windsor, NJ 08520 Made in India NDC 65862-431-74 recalled?

Yes. FDA published recall D-0529-2020 on December 4, 2019. Reported hazard: CGMP Deviations: N-nitrosodimethylamine (NDMA) has been detected in Ranitidine tablets, capsules and syrups.

What should I do if I have this product?

Voluntary: Firm initiated · Press Release